Literature DB >> 3310775

Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine.

E H Bel1, H van der Veen, J A Kramps, J H Dijkman, P J Sterk.   

Abstract

We investigated whether or not leukotriene D4 can influence the maximal degree of airway narrowing in normal humans by comparing the maximal responses to inhaled methacholine and LTD4, and evaluating the interaction between both agonists. In 8 normal subjects, methacholine challenges were performed 24 h before and 24 and 72 h after a LTD4 challenge. Doubling doses of methacholine (1.3 to 655 mumol) or LTD4 (0.007 to 192 nmol) were inhaled by using a recently validated method. The highest dose of LTD4 was followed by the maximal dose of methacholine. The response was measured by FEV1 and volume history standardized partial expiratory flow-volume curves (V40p), and was expressed as percent fall from baseline. All subjects reached a maximal response plateau to both agonists. The maximal response plateau to LTD4 was systematically higher than to methacholine on the preceding day (mean difference, 13.4 and 12.7% fall for FEV1 and V40p, respectively) (p less than 0.01). Addition of methacholine on top of the LTD4 plateau caused a further increase in the response (mean, 6.6 and 4.8% fall, respectively) (p less than 0.005). The maximal responses to methacholine at 24 and 72 h after the LTD4 challenge were higher than at 24 h before (mean difference at 24 h, 4.0 and 8.5% fall for FEV1 and V40p, respectively, and at 72 h 5.7 and 9.3% fall) (p less than 0.05). However, the provocative dose of methacholine causing a 10% fall in FEV1 (PD10) or a 40% fall in V40p (PD40) was not altered by the previous LTD4 challenge test.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3310775     DOI: 10.1164/ajrccm/136.4.979

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Leukotriene receptor antagonists: clinical effects.

Authors:  N Barnes
Journal:  J R Soc Med       Date:  1997-04       Impact factor: 5.344

3.  Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats.

Authors:  D J Hele; M A Birrell; S E Webber; M L Foster; M G Belvisi
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Variability of the plateau response to methacholine in subjects without respiratory symptoms.

Authors:  M D Lougheed; G Pearce-Pinto; N H de Klerk; G Ryan; A W Musk; A James
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 5.  Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.

Authors:  A W Ford-Hutchinson
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis.

Authors:  P Gyllfors; M Kumlin; S-E Dahlén; F Gaber; P-O Ehrs; B Dahlén
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 7.  Regulation of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

8.  Effect of BAY x 7195, an oral receptor antagonist of cysteinyl-leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers.

Authors:  G Wensing; R Heinig; M Priesnitz; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Effects of fluticasone propionate on arachidonic acid metabolites in BAL-fluid and methacholine dose-response curves in non-smoking atopic asthmatics.

Authors:  S E Overbeek; J M Bogaard; I M Garrelds; F J Zijlstra; P G Mulder; H C Hoogsteden
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.